Is CORT or CPRX more undervalued in 2026?

CirclFi compares Corcept Therapeutics Incorporat (CORT) and Catalyst Pharmaceuticals, Inc. (CPRX) using 13 institutional-grade valuation models. CORT has a Quality of Company score of 8.7/10 while CPRX scores 10.0/10.

Which is a better buy — CORT or CPRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CORT and CPRX valuations compare?

CORT at $68.38 and CPRX at $31.29 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CORT vs CPRX Valuation Comparison 2026 — Intrinsic Value Analysis

CORT

Biotechnology

Corcept Therapeutics Incorporat

Quality

8.7

out of 10

Value Trap

LOW

Price

$68.38

Last close

Models

13/13

Active

CPRX

Biotechnology

Catalyst Pharmaceuticals, Inc.

Quality

10.0

out of 10

Value Trap

SAFE

Price

$31.29

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	CORT Fair Value	CORT Upside	CPRX Fair Value	CPRX Upside
Bayesian DCF	Intrinsic	$15.47	-77.4%	$31.62	+1.1%
Earnings Power Value	Intrinsic	$8.28	-83.9%	$18.57	-40.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CORT vs CPRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CORT vs CPRX — Which Stock Is More Undervalued?

CPRX scores higher with a 10.0/10 quality rating vs CORT's 8.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Corcept Therapeutics Incorporat (CORT) and Catalyst Pharmaceuticals, Inc. (CPRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CORT currently trades at $68.38 with a QOC of 8.7/10, while CPRX trades at $31.29 with a QOC of 10.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).